Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein
- PMID: 10698504
- DOI: 10.1038/sj.onc.1203376
Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein
Abstract
The retroviral oncoprotein v-Rel is a member of the Rel/ NF-kappaB family of transcription factors. v-Rel has multiple changes as compared to the proto-oncoprotein c-Rel, and these changes render v-Rel highly oncogenic in avian lymphoid cells. Previous results have shown that three mutant residues in the eleven helper virus-derived Envelope (Env) amino acids (aa) at the N-terminus of v-Rel are required for its full oncogenicity. In this report, we show that these mutant Env aa also enable sequences in the N-terminal half of v-Rel to activate transcription in yeast and chicken cells, under conditions where the analogous sequences from c-Rel either do not or only weakly activate transcription. Removal of the Env aa from v-Rel or site-directed mutations that revert the three mutant residues to the residues present in the Rev-A helper virus Env protein abolish this transactivation ability of v-Rel. Addition of mutant Env aa onto c-Rel is not sufficient to fully restore the transactivation function; other sequences in the N-terminal half of v-Rel are needed for full transactivating ability. A C terminally-truncated form of NF-kappaB p100 (p85), produced in HUT-78 human leukemic cells, also activates transcription in yeast, under conditions where the normal p52 and p100 proteins do not. Furthermore, transcriptional activation by p85 in yeast is likely to occur through N-terminal sequences. Taken together, these results are consistent with a model in which transactivation by N-terminal Rel Homology (RH) domain sequences in oncogenic Rel family proteins is influenced by sequences outside the RH domain.
Similar articles
-
Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.Oncogene. 2000 Jun 29;19(28):3131-7. doi: 10.1038/sj.onc.1203651. Oncogene. 2000. PMID: 10918567
-
Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.Oncogene. 2005 Nov 10;24(49):7355-68. doi: 10.1038/sj.onc.1208902. Oncogene. 2005. PMID: 16027730
-
Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.Oncogene. 1993 Aug;8(8):2245-52. Oncogene. 1993. PMID: 8336947
-
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.Oncogene. 1999 Nov 22;18(49):6925-37. doi: 10.1038/sj.onc.1203222. Oncogene. 1999. PMID: 10602467 Review.
-
Aberrant rel/nfkb genes and activity in human cancer.Oncogene. 1999 Nov 22;18(49):6938-47. doi: 10.1038/sj.onc.1203221. Oncogene. 1999. PMID: 10602468 Review.
Cited by
-
Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation.J Virol. 2002 May;76(10):4928-39. doi: 10.1128/jvi.76.10.4928-4939.2002. J Virol. 2002. PMID: 11967310 Free PMC article.
-
NFκB function and regulation in cutaneous T-cell lymphoma.Am J Cancer Res. 2013 Nov 1;3(5):433-45. Am J Cancer Res. 2013. PMID: 24224122 Free PMC article. Review.
-
NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis.Blood. 2007 Jul 15;110(2):743-51. doi: 10.1182/blood-2006-11-058446. Epub 2007 Apr 3. Blood. 2007. PMID: 17405906 Free PMC article.
-
Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression.J Biol Chem. 2008 Apr 18;283(16):10698-706. doi: 10.1074/jbc.M800806200. Epub 2008 Feb 15. J Biol Chem. 2008. PMID: 18281283 Free PMC article.
-
Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL.Oncogene. 2008 Dec 4;27(53):6770-81. doi: 10.1038/onc.2008.284. Epub 2008 Aug 11. Oncogene. 2008. PMID: 18695674 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources